Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C28H38N2O2.ClH |
| Molecular Weight | 471.074 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.COC1=CC=CC=C1N2CCN(CC[C@](C)(C(=O)C3CCCCC3)C4=CC=CC=C4)CC2
InChI
InChIKey=UUXFKMLSIOTOPP-JCOPYZAKSA-N
InChI=1S/C28H38N2O2.ClH/c1-28(24-13-7-4-8-14-24,27(31)23-11-5-3-6-12-23)17-18-29-19-21-30(22-20-29)25-15-9-10-16-26(25)32-2;/h4,7-10,13-16,23H,3,5-6,11-12,17-22H2,1-2H3;1H/t28-;/m0./s1
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | C28H38N2O2 |
| Molecular Weight | 434.6135 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/12726821 | http://adisinsight.springer.com/drugs/800012905
Curator's Comment: description was created based on several sources, including:
https://www.ncbi.nlm.nih.gov/pubmed/12726821 | http://adisinsight.springer.com/drugs/800012905
Selective, potent, orally bioavailable full 5-HT1A antagonist. S-(+)-enantiomer of (±)-LY426965 is more active in comparison with its opposite enantiomer (R)-(-)-LY 426965. LY426965 completely reversed the effects of nicotine withdrawal on the auditory startle reflex in rats. In microdialysis experiments, LY426965, when administered with fluoxetine, significantly increased extracellular levels of serotonin above those achievable with fluoxetine alone. In electrophysiological studies, the administration of LY426965 both blocked and reversed the effects of fluoxetine on 5-HT neuronal activity. Preclinical results indicate that LY426965 may have clinical use as a pharmacotherapy for smoking cessation and depression and related disorders.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL214 |
4.66 nM [Ki] | ||
Target ID: CHEMBL1833 |
97.3 nM [Ki] | ||
Target ID: CHEMBL1983 |
138.0 nM [Ki] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine. | 2000 Aug |
|
| Asymmetric construction of quaternary centers by enantioselective allylation: application to the synthesis of the serotonin antagonist LY426965. | 2002 May 30 |
|
| Effect of different 5-HT1A receptor antagonists in combination with paroxetine on expression of the immediate-early gene Arc in rat brain. | 2003 Jun |
|
| 5-Hydroxytryptamine 1A (5HT1A) receptors mediate increases in plasma glucose independent of corticosterone. | 2014 Dec 15 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:25:29 GMT 2023
by
admin
on
Fri Dec 15 16:25:29 GMT 2023
|
| Record UNII |
4D59ES6GM9
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
326821-27-6
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
9934447
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY | |||
|
4D59ES6GM9
Created by
admin on Fri Dec 15 16:25:29 GMT 2023 , Edited by admin on Fri Dec 15 16:25:29 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |